Trastuzumab Deruxtecan Shows Intracranial Activity in HER2-Positive Breast Cancer with Active Brain Metastases
A patient-level pooled analysis combining the DEBBRAH and TUXEDO-1 trials along with the DFCI/Duke/MDACC cohort, published in ESMO Open (January 3, 2025), demonstrated clinically meaningful intracranial efficacy of trastuzumab deruxtecan…









